RxDoctor Payments Data

Jacqueline Carruthers, MD

Internal Medicine · Houston, TXNPI 1972504967

Payments from drug & device makers

$1,366in general payments, 2019–2025

Across 85 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$374
  • Novo Nordisk$262
  • Astellas Pharma US Inc$148
  • GSK$107
  • Boehringer Ingelheim$78
  • Sanofi-aventis U.S. LLC$77
  • plus $320 from 8 others

What the payments were for

  • Food & beverage$1,32197%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,366 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,157
Medicare patients
43
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala24$105,491
LinzessLinaclotide74$72,065
OzempicSemaglutide54$63,644
Tresiba Flextouch U-200Insulin Degludec62$58,114
MounjaroTirzepatide43$55,933
TrulicityDulaglutide31$49,420
FarxigaDapagliflozin Propanediol28$32,580
JardianceEmpagliflozin28$27,791
EliquisApixaban25$27,334
JanumetSitagliptin Phos/Metformin Hcl18$17,643
XareltoRivaroxaban11$13,616
SymbicortBudesonide/Formoterol Fumarate36$12,522
Tresiba Flextouch U-100Insulin Degludec16$10,587
Dexlansoprazole DrDexlansoprazole41$9,186
Breo ElliptaFluticasone/Vilanterol15$7,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$71$105,35374 claims
AbbVieLinzess$74$72,06574 claims
Novo NordiskOzempic$262$63,64454 claims
AstraZenecaFarxiga, Symbicort$374$45,10264 claims
Boehringer IngelheimJardiance$78$27,79128 claims
Johnson & JohnsonXarelto$17$13,61611 claims
GSKBreo Ellipta$107$7,45215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →